Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Hematologic Neoplasms 1Cytochrome P450 Interaction 1Advanced Solid Tumor 1ALK-positive Advanced Tumors 1

Interventions

pembrolizumab 11Injections 10tislelizumab 7Nivolumab 4Irinotecan 4Cetuximab 4cediranib 3Paclitaxel 3PM 01183 3Leucovorin 3Gemcitabine 3Fluorouracil 3Cisplatin 3toripalimab 2spartalizumab 2serabelisib 2olaparib 2glumetinib 2camrelizumab 2apatinib 2adagrasib 2Therapeutics 2Pemetrexed 2Oxaliplatin 2Midazolam 2Drug Therapy 2Docetaxel 2Digoxin 2Cyclophosphamide 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumor × Warfarin × Clear all
NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Mirati Therapeutics Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡